IP Library Granted Patent US 7,919,491
Granted Patent B2
US 7,919,491 · App. 12/636,849 · Granted Apr 5, 2011

Pyridine derivatives and their use in the treatment of psychotic disorders

Assignee: GlaxoSmithKline LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,919,491
App. No.
12/636,849
Granted
Apr 5, 2011
Kind
B2
Abstract

A pyridine derivative novel compounds of formula (I) or a pharmaceutically acceptable salt thereof where all variables are defined herein. The compounds are useful in the treatment of psychotic disorders.

Claims (7)

1. A method of treatment of alcohol dependence which comprises administering to a human in need thereof an effective amount of a compound of formula

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound is 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide.

3. The method of claim 1 , wherein the compound is 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide hydrochloride.

4. The method of claim 1 , wherein the compound is administered together with a pharmaceutically acceptable carrier or excipient.

5. The method of claim 2 , wherein the compound is administered together with a pharmaceutically acceptable carrier or excipient.

6. The method of claim 3 , wherein the compound is administered together with a pharmaceutically acceptable carrier or excipient.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2020
From: NERRE THERAPEUTICS LIMITED
To: KANDY THERAPEUTICS LIMITED
Reel/Frame 054687/0378 →
CHANGE OF ADDRESS Recorded Dec 9, 2020
From: NERRE THERAPEUTICS LIMITED
To: NERRE THERAPEUTICS LIMITED
Reel/Frame 054663/0915 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2013
From: GLAXOSMITHKLINE LLC
To: NERRE THERAPEUTICS LIMITED
Reel/Frame 029794/0242 →
Priority Claims (2)
GB 0518472.6 · Sep 9, 2005 · national
GB 0611153.8 · Jun 6, 2006 · national
Continuity (2)
Continuation 12065923
Related Publication 20100152175A1 · Jun 17, 2010